Managing Frontline ADC Side Effects in Metastatic TNBC

In a recent Oncology Nursing News case-based roundtable session, advanced practice providers (APPs) gathered to discuss the shifting clinical paradigm of metastatic triple-negative breast cancer (TNBC) management. The discussion, moderated by Kelsey Martin, APRN, AOCNP, of the Sarah Cannon Research Institute, focused on the emerging clinical role of frontline antibody-drug conjugates (ADCs) for patients with newly diagnosed metastatic disease.

The roundtable provided a valuable collaborative platform for oncology professionals to share real-world insights, discuss emerging clinical trial data, and collaborate on best practices for patient care. These peer interactions remain vital for maintaining contemporary knowledge in rapidly evolving oncological fields. This event highlighted the shared commitment to optimizing patient outcomes.

Traditionally, patients newly diagnosed with metastatic TNBC had limited therapeutic options, often relying almost exclusively on standard single-agent chemotherapy. The introduction and increasing availability of ADCs in this frontline setting represent a highly significant clinical advancement for oncology. Martin explained that having more ADCs available in this therapeutic area is incredibly helpful for patients facing a new diagnosis. By integrating ADCs early in the disease course, oncology clinicians can offer targeted treatment options that delay the necessity of standard chemotherapy to later lines of therapy, thereby shifting the conventional sequencing of metastatic care.

A central theme of the roundtable was the tolerability and clinical management of ADC-related adverse events. While clinical trials have detailed the incidence of adverse events associated with ADCs—including nausea, diarrhea, and neutropenia—participants reported that these toxicities are highly manageable in real-world clinical practice. Martin shared that despite the specific side effects observed in major clinical trials, clinical teams are finding practical ways to manage them "really easily" in daily clinical practice. By proactively anticipating these adverse events, nurses can implement supportive measures before toxicities escalate. The primary clinical goal remains ensuring that patients can successfully receive and continue their prescribed treatments, which is the single most important component of patient care.

This collaborative session allowed attendees to compare regional experiences and validate clinical observations across diverse practice settings in Tennessee. Martin explained that while her clinic at the Sarah Cannon Research Institute frequently observes manageable toxicity profiles, collaborating with other area clinicians reemphasized this positive trend. This professional exchange of clinical strategies ensures a consistent standard of care across regional oncology practices.

By utilizing frontline ADCs, healthcare providers can offer patients effective, targeted therapies early in their treatment course while preserving standard, single-agent chemotherapies for later use. This clinical sequencing strategy is designed to improve the overall tolerability of the treatment journey for patients living with metastatic disease. Ultimately, the discussion underscored how advanced practice providers play a vital role in translating clinical trial data into supportive, patient-centered care. Through diligent monitoring, comprehensive patient education, and early side-effect intervention, oncology teams help patients navigate therapy, maintain treatment adherence, and optimize clinical outcomes in metastatic TNBC.